Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Sandoz Inc. |
---|---|
Information provided by: | Sandoz Inc. |
ClinicalTrials.gov Identifier: | NCT00882700 |
To demonstrate the relative bioequivalence of Cefdinir and Omnicel 300 mg capsule fasting conditions.
Condition | Intervention | Phase |
---|---|---|
Healthy |
Drug: Cefdinir 300 mg Capsule (Sandoz, Austria) Drug: Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA) |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Crossover Assignment |
Official Title: | A Single Center, Open, Randomized, 2-Way, 2-Period, 2-Sequence Crossover Study of the Bioequivalence of 300 mg Cefdinir (Test Formulation) and Omnicel 300 mg Capsule (Reference Formulation) Each Given as a Single Oral Dose to Twenty-Eight Healthy Male and/or Female Volunteers in the Fasting State |
Enrollment: | 28 |
Study Start Date: | April 2005 |
Study Completion Date: | April 2005 |
Primary Completion Date: | April 2005 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Cefdinir 300 mg Capsule (Sandoz, Austria)
|
Drug: Cefdinir 300 mg Capsule (Sandoz, Austria) |
2: Active Comparator
Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
|
Drug: Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA) |
Ages Eligible for Study: | 18 Years to 56 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Sandoz Inc. ( Eric Mittleberg, Ph.D, VP of Product Development ) |
Study ID Numbers: | 50038 |
Study First Received: | April 15, 2009 |
Last Updated: | April 15, 2009 |
ClinicalTrials.gov Identifier: | NCT00882700 History of Changes |
Health Authority: | United States: Institutional Review Board |
Antibiotic |
Cephalosporins Anti-Bacterial Agents Cefdinir Cefixime Healthy |
Anti-Infective Agents Anti-Bacterial Agents Cephalosporins |
Therapeutic Uses Cefdinir Pharmacologic Actions |